secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001193125-25-174982
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen completes dosing in 15 mg/kg cohort of FREEDOM-DM1; net loss narrows to $23.1M
--------------------------------------------------------------------------------

- On track to report topline safety and splicing data from 15 mg/kg cohort in early Q4 2025.
- Concluding FREEDOM trial after 15 mg/kg cohort; transitioning sites to Phase 2 MAD study FREEDOM2-DM1.
- Cash $74.7M sufficient into Q2 2026; net loss $23.1M ($0.70/sh) vs $28.3M ($0.87/sh) YoY.
- Appointed Kasra Kasraian, PhD, as Chief Technology Officer in May 2025.
- FREEDOM2 5 mg/kg cohort results expected Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000119312525174982/0001193125-25-174982-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000119312525174982/pepg-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-174982

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer